On the contrary, in the more recent placebo-controlled REGENT-VSEL study (Transendocardial Delivery of Bone Marrow–Derived CD133+ Cells on Left Ventricle Perfusion and Function in Patients With Refractory Angina) [30], Wojakowski et al. did not report any significant reduction of myocardial ischemia and angina vs placebo after NOGA-guided CD133+ cell intramyocardial injection, although a mild but significant reduction of LV end-systolic and end-diastolic volumes was observed in the cell group only. The gene discussed is PROM1; the disease is angina pectoris.